Opinion|Videos|November 15, 2024
Unmet Needs for Transplant-Eligible NDMM
Key Takeaways
- Pharmacists can enhance medication adherence and manage side effects, crucial for optimizing multiple myeloma therapy.
- Personalized treatment plans should consider patient-specific factors, including comorbidities and genetic profiles.
Panelists discuss how pharmacists can address remaining unmet needs and challenges in optimizing frontline therapy for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM), including areas such as managing complex drug interactions, improving medication adherence, mitigating treatment-related toxicities, streamlining transitions of care, and enhancing patient education and support throughout the treatment journey.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are remaining unmet needs or challenges you see around optimizing frontline therapy for patients with transplant-eligible newly diagnosed multiple myeloma that pharmacists can address?
Advertisement
Related to this article
Persistent symptoms can complicate life after a multiple myeloma treatment response, making routine symptom assessment and targeted supportive care essential.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
4
Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT
5